Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 13/20 | 0.75 |
| ▸ | CNR1 | P21554 | 6/20 | 0.73 |
| ▸ | PPARA | Q07869 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3081674 | 0.94 | CNR1 (0.72) | CNR2CNR1PPARA | |
| SCHEMBL4914114 | 0.93 | CNR2 (0.66) | CNR2CNR1 | |
| SCHEMBL29838956 | 0.88 | CNR2 (0.71) | CNR2CNR1 | |
| SCHEMBL923180 | 0.88 | CNR2 (0.71) | CNR2CNR1 | |
| SCHEMBL3086689 | 0.87 | CNR2 (0.58) | CNR2CNR1PPARA | |
| SCHEMBL6173947 | 0.86 | CNR2 (0.76) | CNR2CNR1PPARA | |
| SCHEMBL30571219 | 0.86 | CNR2 (0.76) | CNR2CNR1PPARA | |
| SCHEMBL276817 | 0.86 | CNR2 (0.76) | CNR2CNR1PPARA | |
| SCHEMBL4246366 | 0.86 | CNR2 (0.76) | CNR2CNR1PPARA | |
| SCHEMBL924033 | 0.86 | CNR2 (0.76) | CNR2CNR1PPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11655238-B2 | MMPL3 inhibitors, compositions and uses thereof | SHANGHAITECH UNIVERSITY (CN) | 2023-05-23 | — | — | US | disclosed |
| US-11655238-B2 | MMPL3 inhibitors, compositions and uses thereof | SHANGHAITECH UNIVERSITY (CN) | 2023-05-23 | — | — | US | disclosed |
| US-20220017492-A1 | MMPL3 INHIBITORS, COMPOSITIONS AND USES THEREOF | SHANGHAITECH UNIVERSITY (CN) | 2022-01-20 | — | — | US | disclosed |
| US-7875646-B2 | Cannabinoid receptor antagonist; N-{[5-(4-chlorophenyl)-4-cyano-1-(2,4-dichlorophenyl)-1H-pyrazol-3-yl]methyl}-3-cyanobenzenesulfonamide; psychiatric disorder, substance dependence and withdrawal disorder, cognitive disorder, ADD, neurodegenerative diseases, pain, eating disorders, dyslipidemia, ulcer | SANOFI-AVENTIS (FR) | 2011-01-25 | — | — | US | disclosed |
| US-20080070962-A1 | DERIVATIVES OF N-[(1,5-DIPHENYL-1H-PYRAZOL-3-YL)METHYL] SULFONAMIDE, THEIR PREPARATION AND THEIR APPLICATION IN THERAPEUTICS | SANOFI-AVENTIS (FR) | 2008-03-20 | — | — | US | disclosed |
| US-7297710-B1 | Derivatives of N-[(1,5-diphenyl-1H-pyrazol-3-yl)methyl]sulfonamide, their preparation and their application in therapeutics | SANOFI-AVENTIS (FR) | 2007-11-20 | — | — | US | disclosed |
| US-7294645-B2 | Derivatives of N′-(1,5-diphenyl-1H-pyrazol-3-yl) sulfonamide with CB1 receptor affinity | SANOFI-AVENTIS (FR) | 2007-11-13 | — | — | US | disclosed |
| US-20070021486-A1 | DERIVATIVES OF N-' (1,5-DIPHENYL-1H-PYRAZOL-3-YL) SULFONAMIDE WITH CB1 RECEPTOR AFFINITY | SANOFI-AVENTIS (FR) | 2007-01-25 | — | — | US | disclosed |
| EP-1556373-A1 | CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | Pfizer Products Inc. (US) | 2005-07-27 | — | — | EP | disclosed |
| WO-2004035566-A1 | CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | PFIZER PRODUCTS INC. (US) | 2004-04-29 | — | — | WO | disclosed |
| US-20040077650-A1 | Cannabinoid receptor ligands and uses thereof | PFIZER INC. | 2004-04-22 | — | — | US | disclosed |
| US-6028084-A | Pyrazole derivatives, method for preparing same, and pharmaceutical compositions containing said derivatives | SANOFI-SYNTHELABO (FR) | 2000-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077650-A1 | Cannabinoid receptor ligands and uses thereof | CNR1, CNR2, GPR18 | CNR2 2/4885CNR1 1/4885PPARA 201/4885 |
| US-20080070962-A1 | DERIVATIVES OF N-[(1,5-DIPHENYL-1H-PYRAZOL-3-YL)METHYL] SULFONAMIDE, THEIR PREPARATION AND THEIR APPLICATION IN THERAPEUTICS | PRMT5, PRMT3, PRMT1 | CNR2 89/4885CNR1 93/4885PPARA 2880/4885 |
| US-11655238-B2 | MMPL3 inhibitors, compositions and uses thereof | TIMP3, AFG3L2, MMP3 | CNR2 4645/4885CNR1 4650/4885PPARA 3243/4885 |
| US-20220017492-A1 | MMPL3 INHIBITORS, COMPOSITIONS AND USES THEREOF | TIMP3, AFG3L2, MMP3 | CNR2 4645/4885CNR1 4650/4885PPARA 3243/4885 |
| US-20070021486-A1 | DERIVATIVES OF N-' (1,5-DIPHENYL-1H-PYRAZOL-3-YL) SULFONAMIDE WITH CB1 RECEPTOR AFFINITY | CNR1, CNR2, NPSR1 | CNR2 2/4885CNR1 1/4885PPARA 563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.